Thrombocytopenia is one of the most common non-criteria findings in APS patients. The estimated prevalence of thrombocytopenia in patients with APS ranged from 20 to 53%, depending on the cut-off value used (<100 x 10^9/L or <150 x 10^9/L), and the frequency of patients with primary APS (PAPS) and secondary APS...
(SAPS) in the studied cohort.6-8 Interestingly, the prevalence of thrombocytopenia may reach up to 65 to 100% in patients with catastrophic APS (CAPS).8,9 Thus, some authors have suggested that a progressive decrease in the platelet count in APS patients may be considered a sign for progressive disease and be a risk factor for developing CAPS in the future.1,10 Furthermore, Artim-Esen et al.4 reported coexistence of thrombocytopenia and neuropsychiatric manifestations, in association with lupus anticoagulant and high titers of anticardiolipin antibodies.

Although several studies have been conducted on thrombocytopenia in APS patients to date,6,11-13 there are important issues that still need to be addressed, such as relation of thrombocytopenia to clinical associations of APS, its effect on the disease outcomes, and finally the relation of thrombocytopenia to the APS damage index (DIAPS). In the present study, we aimed to evaluate the prevalence of thrombocytopenia in patients with APS and to examine the relation of thrombocytopenia to the clinical and laboratory findings, and DIAPS.

**PATIENTS AND METHODS**

This single-center, retrospective study was conducted at Cairo University Hospital, Faculty of Medicine, Department of Rheumatology, between August 2018 and February 2019. A total of 168 patients (16 males, 152 females; mean age: 32.5±8.4 years; range, 18 to 59 years) who were followed in our clinic and fulfilled the update of Sapporo Classification Criteria for definite APS14 were included. The medical records were revised for demographic data, clinical features of the disease, immune profile, routine laboratory investigations, and treatments applied. In addition, the DIAPS15 was calculated for all patients. The patients were divided into two groups according to the presence or absence of thrombocytopenia and both groups were compared regarding demographic data, clinical, laboratory findings, treatments, and DIAPS. Patients less than 18 years old or with disease duration of less than two years were excluded from the study. Thrombocytopenia was considered a clinical feature of APS in our study, when the platelet count of less than 150×10^9/L was found on a minimum of two occasions.11 Further subgroup analysis was done for patients with PAPS according to the presence or absence of thrombocytopenia.

**Statistical analysis**

Statistical analysis was performed using the SPSS for Windows version 23.0 software (IBM Corp., Armonk, NY, USA). Descriptive data were expressed in mean ± standard deviation (SD) or median (min-max) for quantitative variables and in number and frequency for qualitative variables. Comparison between the groups was conducted using the Student t-test for normally distributed data and Mann-Whitney U test for skewed data. The chi-square test was used analyze qualitative variables. A p value of <0.05 was considered statistically significant.

**RESULTS**

The mean disease duration was 9.3±6.1 years, and the mean age at onset was 23.3±7.6 years. Forty-five (26.8%) patients had PAPS, 116 (69%) patients had APS secondary to systemic lupus erythematosus (SLE), while seven (4.2%) patients had APS secondary to other diseases. The most commonly reported manifestations in our patients were obstetric manifestations (77.4% in pregnant women), musculoskeletal manifestations (69%), and peripheral vascular thrombosis (54.8%) (Table 1).

The laboratory features of our patients in the last visit, their treatment and DIAPS are shown in Table 2. Our patients were divided into two groups according to presence or absence of thrombocytopenia, the two groups were compared regarding demographic, clinical, laboratory, treatments, and DIAPS as shown in Table 3. Furthermore, we studied patients with PAPS to exclude any impact of associated disease, and we divided them into two groups according to the presence or absence of thrombocytopenia and both groups were compared regarding the previously mentioned items as shown in Table 4.

**DISCUSSION**

The estimated prevalence of thrombocytopenia in APS in the literature ranges between
| Table 1. Demographic data, clinical manifestations, and immune profile of APS patients (n=168) |
|-------------------------------------------------|--------------------|----------------|----------------|---------------|
|                                                  | n      | %    | Mean±SD  | Range | Median | IQR  |
| Age (year)                                       | 32.5±8.5 | 18-59 | 32    | 26-37 |
| Sex                                              |        |      |        |       |        |
| Male                                             | 9.5   | 16   |        |       |        |
| Female                                           | 90.5  | 152  |        |       |        |
| Age at onset (year)                              | 23.3±7.6 | 11-52 | 22    | 18-25 |
| Disease duration (year)                          | 9.3±6.1 | 1-41  | 8     | 4.5-13 |
| Time till diagnosis (year)                       | 3±3.8  | 0-25  | 2     | 0.3-4.5 |
| Obstetric manifestations related to APS          | 103    | 77.4 |        |       |        |
| Musculoskeletal manifestations                   | 116    | 69   |        |       |        |
| Hematological manifestations (anemia-leukopenia-thrombocytopenia) | 81 | 48.2 | | |
| Hemolytic anemia                                 | 24     | 14.3 |        |       |        |
| Thrombocytopenia at onset                        | 51     | 30.4 |        |       |        |
| Thrombocytopenia throughout disease             | 71     | 42.3 |        |       |        |
| Constitutional manifestations                    | 86     | 51.2 |        |       |        |
| Peripheral vascular thrombosis                   | 92     | 54.8 |        |       |        |
| Venous thrombosis                                | 78     | 46.4 |        |       |        |
| Arterial thrombosis                              | 24     | 14.3 |        |       |        |
| Neurological manifestations                      | 69     | 41.1 |        |       |        |
| (Seizures, stroke, TIA, psychosis)               |        |      |        |       |        |
| Cardiovascular manifestations                    | 68     | 40.5 |        |       |        |
| (Valve disease, pericardial effusion, coronary vascular disease) | | | | |
| Cutaneous manifestations                         | 56     | 33.3 |        |       |        |
| (Thrombophlebitis,digital gangrene, cutaneous ulcers, livido reticularis) | | | | |
| Pulmonary manifestations                          | 34     | 20.2 |        |       |        |
| (Pulmonary hypertension, embolism, insufficiency) | | | | |
| Renal manifestations                              | 61     | 36.3 |        |       |        |
| (Nephritis, thrombotic microangiopathy, renal failure, renal artery/vein thrombosis) | | | | |
| Ophthalmological manifestations                   | 11     | 6.5  |        |       |        |
| (Retinal vasculitis, retinal thrombosis)         |        |      |        |       |        |
| Hepatic and GI manifestations                     | 6      | 3.6  |        |       |        |
| (Budd chiari and mesenteric thrombosis)          |        |      |        |       |        |
| Associated disease                               | 56     | 33.3 |        |       |        |
| Hypertension                                     | 43     | 25.6 |        |       |        |
| Diabetes                                         | 11     | 6.5  |        |       |        |
| Others                                           | 11     | 6.5  |        |       |        |
| Antinuclear antibody                             | 127    | 75.6 |        |       |        |
| Anti-double-stranded deoxyribonucleic acid       | 59     | 35.1 |        |       |        |
| Lupus anticoagulant                              | 97     | 57.7 |        |       |        |
| ACL IgG                                          | 86     | 51.2 |        |       |        |
| ACL IgM                                          | 54     | 32.1 |        |       |        |
| Anti-B2 glycoprotein IgG                         | 41     | 24.4 |        |       |        |
| Anti-B2 glycoprotein IgM                         | 26     | 15.5 |        |       |        |

APS: Antiphospholipid syndrome; SD: Standard deviation; IQR: Interquartile range; TIA: Transient ischemic attack; GI: Gastrointestinal; ACL: Anti-cardiolipin antibodies; Ig: Immunoglobulin.
20 and 50%, which is consistent with our results (42.3%). The similarity in the frequency of thrombocytopenia between males and females in the current study (43.75% and 42.1%) is in accordance with that reported in previous studies.6,7

Regarding obstetric manifestations, we could not detect significant associations between thrombocytopenia and obstetric morbidity in our patients. On the other hand, our results showed a high rate of overall neurological manifestations in thrombocytopenia group compared to non-thrombocytopenia group (50.7% vs. 34%) with a statistically significant difference (p=0.03). We also found a strong association between thrombocytopenia and musculoskeletal manifestations (77.5% vs. 62.9%) (p=0.043). Similarly, Krause et al.6 reported that obstetric complications were similar in patients with and without thrombocytopenia and that the presence of thrombocytopenia might be a risk factor for neurological and articular manifestations. Also, Artim-Esen et al.4 reported that thrombocytopenia represents a risk factor for thrombosis and neurological manifestations in aPL-positive patients.

Our results showed a high rate of venous thrombosis in thrombocytopenia group compared to the other, but also this was not statistically significant (18.3% vs. 11.3%) (p=0.202). Also, total peripheral vascular thrombosis was higher in the positive group compared to the negative group (63.4% vs. 48.5%), with a p value quite close to the significant value (p=0.055). Comparing the two groups regarding total thrombotic events (peripheral vascular and internal organs), thrombocytopenia group showed a higher incidence of total thrombosis (77.5% vs. 62.9%) with a significant p value of 0.043, although the rate of thrombosis in the study conducted by Krause et al.6 was slightly higher in the thrombocytopenia group; however, it did not reach statistical significance. On the other hand, Atsumi et al.16 reported that the presence of thrombocytopenia in patients with APS was not typically associated with hemorrhagic complications; rather, it could trigger thrombotic events. It was also found that the more severe the thrombocytopenia, the higher the possibility of future thrombosis. Also, Pontara et al.8 reported that a decrease in platelet count was associated with the development of the catastrophic form of the disease, a decrease in platelet count in high-risk APS patients should be evaluated cautiously for the disease progression to CAPs.

Furthermore, our results are in accordance with Demetrio Pablo et al., as they reported that aPL-positive patients who developed thrombocytopenia had a potential risk of developing thrombosis. In addition,
Table 3. Comparison of all APS patients included in our cohort according to presence and absence of thrombocytopenia

|                                      | +VE (n=71) |                                      | -VE (n=97) |                                      | p     |
|--------------------------------------|------------|--------------------------------------|------------|--------------------------------------|-------|
|                                       | n          | %                                    | Mean±SD    | Range      | Median   | IQR     | n          | %                                    | Mean±SD    | Range      | Median   | IQR     |
| Age (year)                           | 31.7±9     | 18-59                                | 30         | 24-38     |          |        | 33.1±8.1   | 18-55                                | 32         | 28-37      |          |        |
| Sex                                  | 7          | 9.9                                  | 64         | 90.1      |          |        | 9          | 9.3                                  | 88         | 90.7       |          |        |
| Age at onset (year)                  | 23±7.9     | 12-45                                | 21         | 18-25     | 23.4±7.3 | 11-52   | 22         | 19.26                               | 0.742#     |           |          |        |
| Disease duration (year)              | 8.7±6.9    | 1.41                                 | 7          | 4.11      | 9±5.3    | 1-26    | 9          | 5-14                                 | 0.058†     |           |          |        |
| Time till diagnosis (year)           | 3.3±4.5    | 0.25                                 | 1          | 0.35      | 2.8±3.2  | 0-14    | 2          | 0.44                                 | 0.058†     |           |          |        |
| Obstetric manifestations             | 43         | 74.1                                 | 60         | 80        |          |        | 61         | 62.9                                | 0.422#     |           |          |        |
| Musculoskeletal manifestations       | 55         | 77.5                                 | 61         | 62.9      |          |        | 100        | 100.0                               | 0.043*     |           |          |        |
| Hemolytic anemia                     | 14         | 19.7                                 | 10         | 10.3      |          |        | 46         | 47.4                                | 0.253*     |           |          |        |
| Systemic manifestations              | 40         | 56.3                                 | 46         | 47.4      |          |        | 91         | 90.1                                | 0.085*     |           |          |        |
| Vascular thrombosis (Peripheral and internal organs) | 55       | 77.5                                 | 61         | 62.9      |          |        | 100        | 100.0                               | 0.043*     |           |          |        |
| Peripheral vascular thrombosis       | 45         | 63.4                                 | 47         | 48.5      |          |        | 80         | 81.6                                | 0.055*     |           |          |        |
| Venous thrombosis                    | 36         | 50.7                                 | 42         | 43.3      |          |        | 46         | 47.4                                | 0.342*     |           |          |        |
| Arterial thrombosis                  | 13         | 18.3                                 | 11         | 11.3      |          |        | 15         | 15.5                                | 0.202*     |           |          |        |
| Neurological manifestations          | 36         | 50.7                                 | 33         | 34        |          |        | 25         | 25.4                                | 0.175*     |           |          |        |
| Cardiovascular manifestations        | 33         | 46.5                                 | 35         | 36.1      |          |        | 25         | 25.4                                | 0.030†     |           |          |        |
| Cutaneous manifestations             | 32         | 45.1                                 | 24         | 24.7      |          |        | 25         | 25.4                                | 0.046†     |           |          |        |
| Pulmonary manifestations             | 14         | 19.7                                 | 20         | 20.6      |          |        | 35         | 36.1                                | 0.943*     |           |          |        |
| Renal manifestations                 | 26         | 36.6                                 | 35         | 36.1      |          |        | 35         | 36.1                                | 0.943*     |           |          |        |
| Ophthalmological manifestations      | 7          | 9.9                                  | 4          | 4.1       |          |        | 15         | 15.5                                | 0.206*     |           |          |        |
| Hepatic and GIT manifestations       | 4          | 5.6                                  | 2          | 2.1       |          |        | 20         | 20.6                                | 0.242*     |           |          |        |
| Antinuclear antibody                 | 56         | 78.9                                 | 71         | 73.2      |          |        | 75         | 75.6                                | 0.397*     |           |          |        |
| Anti-double-stranded deoxyribonucleic acid | 22    | 31                                   | 37         | 38.1      |          |        | 37         | 38.1                                | 0.337*     |           |          |        |
| Lupus anticoagulant                  | 43         | 60.6                                 | 54         | 55.7      |          |        | 55         | 55.7                                | 0.526*     |           |          |        |
| ACL IgG                              | 37         | 52.1                                 | 49         | 50.5      |          |        | 49         | 50.5                                | 0.838*     |           |          |        |
| ACL IgM                              | 25         | 35.2                                 | 29         | 29.9      |          |        | 29         | 29.9                                | 0.466*     |           |          |        |
| Anti-B2 glycoprotein IgG             | 16         | 22.5                                 | 25         | 25.8      |          |        | 25         | 25.8                                | 0.629*     |           |          |        |
| Anti-B2 glycoprotein IgM             | 11         | 15.5                                 | 15         | 15.5      |          |        | 20         | 20.6                                | 0.996*     |           |          |        |
| Hemoglobin                           | 11±1.8     | 6.7-18.6                              | 10.7       | 9.7-12    | 11±1.8   | 6.9-15.8| 11.2       | 10-12.5                              | 0.571#     |           |          |        |
| Total leucocytic count               | 6.8±2.6    | 2.4-15                                | 6.9        | 5-8.4     | 8±2.9    | 0.5-6.6 | 7          | 5±8.2                               | 0.372†     |           |          |        |
| Erythrocyte sedimentation rate       | 41±26.7    | 2-113                                 | 33         | 20-55     | 41±40.9  | 5-337   | 30         | 18-50                                | 0.389†     |           |          |        |
| Anticoagulation                      | 53         | 74.6                                 | 66         | 68        |          |        | 68         | 68.2                                | 0.352*     |           |          |        |
| Antiplasmin                          | 65         | 91.5                                 | 85         | 87.6      |          |        | 87         | 87.6                                | 0.417*     |           |          |        |
| Corticosteroids                      | 62         | 87.3                                 | 79         | 81.4      |          |        | 81         | 81.4                                | 0.305*     |           |          |        |
| Antimalarial                         | 62         | 87.3                                 | 77         | 79.4      |          |        | 78         | 78.6                                | 0.178*     |           |          |        |
| Immunosuppressive treatment          | 58         | 81.7                                 | 66         | 68        |          |        | 68         | 68.2                                | 0.047*     |           |          |        |
| DIAPS                                | 2.6±2.3    | 0-9                                  | 2          | 1-4       | 1.9±1.9  | 0-8     | 1          | 0-3                                  | 0.034†     |           |          |        |

APS: Antiphospholipid syndrome; SD: Standard deviation; IQR: Interquartile range; GIT: Gastrointestinal tract; ACL: Anti-cardiolipin antibodies; Ig: Immunoglobulin; DIAPS: Damage index for antiphospholipid syndrome; * Chi square test; † Student t-test; ‡ Mann-Whitney U test.
Table 4. Comparison of APS patients included in our cohort according to presence and absence of thrombocytopenia (n=45)

|                                     | Thrombocytopenia throughout disease | Without Thrombocytopenia | p      |
|-------------------------------------|-------------------------------------|--------------------------|--------|
|                                     | Yes (n=15)                          | No (n=30)                |        |
| Age (year)                          | 30.7±7.8 22-47 29 24-37            | 31.8±7 20-48 32.5 26-36 | 0.562† |
| Sex                                 |                                     |                          |        |
| Male                                |                                     |                          |        |
| Female                              |                                     |                          |        |
|                                     | 0 0                                 | 2 28                     | 0.545* |
| Age at onset (year)                 | 21.7±8.4 13-43 19 17-22             | 23±5.5 16-40 21.5 19-25 | 0.074† |
| Disease duration (year)             | 8.9±7.5 1-24 6 3-16                 | 8.8±5 2-18 8 4-12        | 0.612† |
| Time till diagnosis (year)          | 3.6±3.7 0-12 3 0.3-5                | 3.7±3.1 0-14 3 2-5       | 0.698† |
| Obstetric manifestations            | 12 80                               | 24 88.9                  | 0.649* |
| Musculoskeletal manifestations      | 9 60                                | 9 30                     | 0.053* |
| Hemolytic anemia                    | 2 13.3                              | 0 0                      | 0.106* |
| Constitutional manifestations       | 6 40                                | 4 13.3                   | 0.062* |
| Vascular manifestations             | 9 60                                | 12 40                    | 0.205* |
| Venous thrombosis                   | 5 33.3                              | 9 30                     | 1.000* |
| Arterial thrombosis                 | 6 40                                | 4 13.3                   | 0.062* |
| Neurological manifestations         | 8 53.3                              | 4 13.3                   | 0.010* |
| Cardiovascular manifestations       | 3 20                                | 6 20                     | 1.000* |
| Cutaneous manifestations            | 6 40                                | 5 16.7                   | 0.140* |
| Pulmonary manifestations            | 1 6.7                               | 6 20                     | 0.395* |
| Renal manifestations                | 2 13.3                              | 2 6.7                    | 0.591* |
| Ophthalmological manifestations     | 1 6.7                               | 1 3.3                    | 1.000* |
| Hepatic and GIT manifestations      | 1 6.7                               | 1 3.3                    | 1.000* |
| Antinuclear antibody                | 3 20                                | 6 20                     | 1.000* |
| Anti-double-stranded deoxyribonucleic acid | 0 0                              | 0 0                     | .....  |
| Lupus anticoagulant                 | 12 80                               | 23 76.7                  | 1.000* |
| ACL lgG                             | 8 53.3                              | 13 43.3                  | 0.526* |
| ACL lgM                             | 7 46.7                              | 7 23.3                   | 0.172* |
| Anti-B2 glycoprotein lgG            | 3 20                                | 6 20                     | 1.000* |
| Anti-B2 glycoprotein lgM            | 3 20                                | 1 3.3                    | 0.101* |
| Hemoglobin                          | 10±9 14 8-5 13 10.9 10-12            | 11±14 8-13 11.3 10-12    | 0.647† |
| Total leucocytic count             | 7±1.7 5-11 78 7-9                   | 10±6 13.3 4-66 7 5-9.1   | 0.372† |
| Erythrocyte sedimentation rate      | 36±6.25 10-110 30 20-50             | 42±4.60 2 6-337 25 18-43 | 0.491† |
| Anticoagulation                     | 14 93.3                             | 26 86.7                  | 0.651* |
| Antiplatelet                        | 14 93.3                             | 27 90                    | 1.000* |
| Corticosteroids                     | 6 40                                | 14 46.7                  | 0.671* |
| Antimalarial                        | 11 73.3                             | 20 66.7                  | 0.743* |
| Immunosuppressive treatment         | 4 26.7                              | 5 16.7                   | 0.454* |
| DIAPS                               | 2.1±2.2 0.6 1 0.4                   | 11±1.7 0.6 0 0.2         | 0.082† |

APS: Antiphospholipid syndrome; SD: Standard deviation; IQR: Interquartile range; GIT: Gastrointestinal tract; ACL: Anti-cardiolipin antibodies; lg: Immunoglobulin; DIAPS: Damage index for antiphospholipid syndrome; * Chi square test; † Mann-Whitney U test.
Abreu et al.\textsuperscript{18} showed that thrombocytopenia in APS was a consequence of consumption of platelets, as binding of aPL antibodies, particularly anti-beta-2 glycoprotein antibodies, to the surface of activated platelets promoted their aggregation and thrombus formation. Finally, Proulle et al.\textsuperscript{19} showed that, among aPL-positive patients, thrombosis might develop more frequently in patients with a low platelet count, compared to those without.

Although Krause et al.\textsuperscript{6} found significant associations between thrombocytopenia and cardiac valves thickening and dysfunction, our results showed no statistically significant difference between the two groups regarding overall cardiac manifestations.

Regarding cutaneous manifestations (cutaneous ulcers, digital gangrene, livedo, thrombophlebitis), our results showed an overall increase in the rate of cutaneous manifestations in the thrombocytopenia group compared to the other group (45.1\% vs. 24.6\%) with a statistically significant difference (p=0.006). Similarly, Krause et al.\textsuperscript{6} and Comellas-Kirkerup et al.\textsuperscript{20} reported significant associations between thrombocytopenia and cutaneous manifestations including livedo reticularis and skin ulcerations. Furthermore, many reports have suggested that livedo reticularis may be associated with more severe disease, as it may be associated with thrombosis,\textsuperscript{21} and also it may be associated with stroke.\textsuperscript{22} In our study, both thrombosis and stroke were significantly higher in the thrombocytopenia group and this is in line with the findings of Artim-Esen et al.\textsuperscript{4} Moreover, the association of thrombocytopenia with neurological manifestations was also confirmed in our PAPS cohort.

The significantly higher usage of immunosuppressive in the thrombocytopenia group, in our study, was expected as thrombocytopenia, particularly if severe, may require treatment with high dose glucocorticoids, immunosuppressive drugs, and rituximab along with intravenous immunoglobulin and plasma exchange.\textsuperscript{23-25}

Damage index for APS was significantly higher in thrombocytopenia group (p=0.034). This may be a sequence of the higher prevalence of neurological manifestations, thrombosis and cutaneous manifestations, all of which may be associated with more damage. Also, thrombocytopenia itself may be a sign of more aggressive disease and may require treatment with immunosuppressors adding to the disease burden and may affect the disease outcome. To the best of our knowledge, no previous study has compared damage accrual in APS patients with and without thrombocytopenia; however, Ruiz-Frastorza et al.\textsuperscript{26} concluded that APS associated with thrombosis might present more damage in SLE. Furthermore, Artim-Esen et al.\textsuperscript{4} reported that thrombocytopenia was a risk factor for thrombosis in aPL-positive patients. All the aforementioned data may give a reasonable explanation of the higher damage index in the thrombocytopenia group.

On analyzing PAPS patients and although DIAPS was higher in PAPS patients with thrombocytopenia (2.1±2.2) compared to (1.1±1.7) in those without, the difference did not reach statistical significance (p=0.082). Similarly, venous thrombosis, arterial thrombosis, and total peripheral vascular thrombosis were higher in thrombocytopenia group; however, the difference did not reach statistical significance (p=0.062). The lack of association of thrombocytopenia with DIAPS and arterial thrombosis, although p value quite close to significant in both situations, may be due to the small sample size of patients with PAPS in the current cohort. In our opinion, thrombocytopenia may represent more than an incidental laboratory finding in APS patients and further studies may be needed to explore its role in APS pathogenesis and in damage occurrence in APS patients.

The small number of patients with PAPS included in the current study is the main limitation. We, therefore, recommend further studies on thrombocytopenia to be conducted on a large cohort of PAPS patients to avoid the impact of any associated disease as SLE on APS characteristics and DIAPS.

In conclusion, thrombocytopenia may be associated with higher incidence of vascular thrombosis, neurological manifestations, musculoskeletal manifestations, use of immunosuppressive treatment, and DIAPS. In PAPS patients, thrombocytopenia may be a risk for neurological manifestations; however further large-scale studies are needed to confirm our findings.
**Ethics Committee Approval:** The study protocol was approved by the local department committee in June 2018 and by the faculty post graduate research committee in 15 August 2018. The study was conducted in accordance with the principles of the Declaration of Helsinki.

**Data Sharing Statement:** The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Author Contributions:** All authors contributed equally to the article: S.G., S.M., A.M.

**Conflict of Interest:** The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

**Funding:** The authors received no financial support for the research and/or authorship of this article.

**REFERENCES**

1. Linnemann B. Antiphospholipid syndrome - an update. Vasa 2018;47:451-64.
2. Omar G, Mohamed FI, Sadek HA, Mamdouh AS. Diagnostic value of anti-annexin A5 antibodies in seropositive versus seronegative antiphospholipid syndrome patients. The Egyptian Rheumatologist 2018;40:111-6.
3. Cervera R. Antiphospholipid syndrome. Thromb Res 2017;151 Suppl 1:S43-S47.
4. Artim-Esen B, Diz-Küçükkaya R, İnanç M. The significance and management of thrombocytopenia in antiphospholipid syndrome. Curr Rheumatol Rep 2015;17:14.
5. Cervera R, Tektonidou MG, Espinosa G, Cabral AR, González EB, Erkan D, et al. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): Thrombocytopenia and skin manifestations. Lupus 2011;20:174-81.
6. Krause I, Blank M, Fraser A, Lorber M, Stojanovich L, Roversi J, et al. The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome. Immunobiology 2005;210:749-54.
7. Cervera R, Piette JC, Font J, Khamashta MA, Shoenefeld Y, Camps MT, et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019-27.
8. Pontara E, Banzato A, Bion E, Cattini MG, Baroni G, Denas G, et al. Thrombocytopenia in high-risk patients with antiphospholipid syndrome. J Thromb Haemost 2018;16:529-32.
9. Cervera R, Rodríguez-Pintó I, Colafrancesco S, Conti F, Valesini G, Rosário C, et al. 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. Autoimmun Rev 2014;13:699-707.
10. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-86.
11. Cuadrado MJ, Mujic F, Muñoz E, Khamashta MA, Hughes GR. Thrombocytopenia in the antiphospholipid syndrome. Ann Rheum Dis 1997;56:194-6.
12. Galli M, Finazzi G, Barbui T. Thrombocytopenia in the antiphospholipid syndrome: Pathophysiology, clinical relevance and treatment. Ann Med Interne (Paris) 1996;147 Suppl 1:24-7.
13. de Groot PG. Platelets as pivot in the antiphospholipid syndrome. Blood 2014;124:475-6.
14. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
15. Amigo MC, Goycochea-Robles MV, Espinosa-Cuervo G, Medina G, Barragán-Garfias JA, Vargas A, et al. Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS). Lupus 2015;24:927-34.
16. Atsumi T, Furukawa S, Amengual O, Koike T. Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus 2005;14:499-504.
17. Demetrio Pablo R, Muñoz P, López-Hoyos M, Calvo V, Riancho L, Martínez-Taboada VM. Thrombocytopenia as a thrombotic risk factor in patients with antiphospholipid antibodies without disease criteria. Med Clin (Barc) 2017;148:394-400.
18. Abreu MM, Danowski A, Wahl DG, Amigo MC, Tektonidou M, Pacheco MS, et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev 2015;14:401-14.
19. Proulle V, Furie RA, Merrill-Skoloff G, Furie BC, Furie B. Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. Blood 2014;124:611-22.
20. Comellas-Kirkerup L, Hernández-Molina G, Cabral AR. Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: A 6-year follow-up study. Blood 2010;116:3058-63.
21. Toubi E, Shoenefeld Y. Livedo reticularis as a criterion for antiphospholipid syndrome. Clin Rev Allergy Immunol 2007;32:138-44.
22. Matyja-Bednarczyk A, Swadźba J, Iwaniec T, Sanak M, Dziedzina S, Cmiel A, et al. Risk factors for arterial
thrombosis in antiphospholipid syndrome. Thromb Res 2014;133:173-6.

23. Gamoudi D, Cutajar M, Gamoudi N, Camilleri DJ, Gatt A. Achieving a satisfactory clinical and biochemical response in antiphospholipid syndrome and severe thrombocytopenia with rituximab: Two case reports. Clin Case Rep 2017;5:845-8.

24. Pons-Estel GJ, Andreoli L, Scanzi F, Cervera R, Tincani A. The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun 2017;76:10-20.

25. Martirosyan A, Petrek M, Kishore A, Manukyan G. Immunomodulatory effects of therapeutic plasma exchange on monocytes in antiphospholipid syndrome. Exp Ther Med 2016;12:1189-95.

26. Ruiz-Irastorza G, Egurbide MV, Ugalde J, Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 2004;164:77-82.